Gefitinib, erlotinib or afatinib represent standard of care as first-line treatment for advanced non-small cell lung cancer (NSCLC) harbouring an activating mutation of epidermal growth factor receptor (EGFR). The toxicity profile of these drugs is well known with rash, diarrhoea, nausea, anorexia, fatigue and derangement of liver function being the most commonly observed adverse events. We report a case of an 82-year-old patient with EGFR-mutant advanced NSCLC who developed gefitinib-induced acute kidney injury, which slowly improved on discontinuation of the drug.
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Adverse events associated with gefitinib are well known and include rash, pruritus, diarrhoea, nausea, anorexia, fatigue, derangement of liver function tests and, rarely, interstitial lung disease. Renal impairment was not recorded as an adverse event in randomised phase III trials evaluating gefitinib as first-line therapy in advanced EGFR-mutant NSCLC. [2] [3] [4] Gefitinib metabolism is mainly hepatic and its excretion predominantly gastrointestinal. Renal elimination accounts for less than 4 % of an administered dose 5 and it has safely been administered to patients with chronic renal impairment. 6 While cases of acute kidney injury have been reported with other anti-EGFR treatments, such as cetuximab, 7 it has not been reported with gefitinib in the Western population.
We report a case of a patient with EGFR-mutant advanced NSCLC who developed acute kidney injury during treatment with gefitinib, which slowly improved on discontinuation of the drug.
Case Report
An 82-year-old Caucasian male ex-smoker presented with a 4-month Since discharge his sCr continued to improve but never returned to baseline 6 months following the acute admission. The trend of kidney function tests is shown in Table 1 .
On further follow up in the clinic patient remained well in himself (PS 1) with no evidence of progression and was kept under regular review in order to consider further treatment at progression. 
Discussion
Gefitinib, is usually well tolerated and associated with significant lower rates of adverse events and discontinuation of therapy due to treatment-related adverse events compared with chemotherapy.
2-4
Although there has been one case reported of gefitinib-induced nephrotic syndrome, 8 acute kidney injury is not a common adverse event and to our knowledge it has only been reported once in a patient of East Asian ethnicity. 9 Our case subject did have mild chronic kidney disease at baseline likely secondary to a combination of hypertensive nephrosclerosis and diabetic glomerulonephropathy. However, his renal function dramatically deteriorated following the introduction of gefitinib and multiple investigations failed to identify a clear precipitating cause.
Discontinuing gefitinib led to an improvement in both sCr and creatinine clearance, strongly suggesting that it was the cause. Both parameters have failed to return to baseline implying a degree of underlying permanent nephrotoxic damage secondary to gefitinib.
There is evidence to support safe administration of gefitinib in patients with renal impairment and even haemodialysis.
6,10 However, we highlight the need for caution in patients with predisposing renal risk factors.
Switching to erlotinib has been successful in case of more common gefitinib-related adverse events such as hepatotoxicity, pneumonitis and severe neutropenia, 11 but it is not known if this is a safe strategy in the event of acute kidney failure.
Interestingly, there is increasing preclinical evidence to suggest that EGFR activation and the subsequent activation of down stream signalling pathways play a vital role in functional recovery following acute kidney injury. Earlier studies in rat models with post-ischaemic or toxicity-induced acute kidney injury have shown that exogenous administration of EGF enhances tubular cell regeneration and results in lower peak urea and creatinine levels and quicker recovery time from acute kidney failure. [12] [13] [14] [15] Recent studies have evaluated the effect of EGFR inhibition in acute renal failure. Zhuang et al. used a murine model of folic acid induced acute kidney injury to study the effect of EGFR inactivation using waved 2 mice with reduced EGFR activity and mice that had received gefitinib. This study demonstrated that, compared to mice with normal EGFR activity, the EGFR inactivation resulted in reduced renal tubular cell regeneration and increased renal damage, as it was shown by the higher urea and creatinine levels. 16 Furthermore, a murine study by Chen et al. demonstrated markedly delayed recovery following ischaemic-reperfusion injury in renal proximal tubule cell-specific EGFR deletion mice and wild-type mice treated with erlotinib. 17 These findings warrant further evaluation and may be of particular relevance to patients already pre-disposed to renal complications.
We suggest careful monitoring of renal function in patients receiving gefitinib and to consider immediate discontinuation of therapy in the face of acute renal deterioration. n 
